• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Fusion Pharmaceuticals Inc. (Amendment)

    4/8/24 9:10:09 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FUSN alert in real time by email
    SC 13G/A 1 form1745fusion.htm

    OMB APPROVAL

    OMB Number: 3235-0145

    Estimated average burden hours per response ….11

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3*)

    FUSION PHARMACEUTICALS, INC.

    (Name of Issuer)

    COMMON STOCK

    (Title of Class of Securities)

    36118A100

    (CUSIP Number)

    March 31, 2024

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    X Rule 13d-1(b)
      Rule 13d-1(c)
      Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     
     

     

    CUSIP No.: 36118A100

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Federated Hermes, Inc.
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: Pennsylvania

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:       95,000
    6. Shared Voting Power
    7. Sole Dispositive Power:       95,000
    8. Shared Dispositive Power

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:       95,000
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  .11%
    12. Type of Reporting Person (See Instructions): HC

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Voting Shares Irrevocable Trust
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: Pennsylvania

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:       95,000
    6. Shared Voting Power
    7. Sole Dispositive Power:       95,000
    8. Shared Dispositive Power

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:       95,000
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  .11%
    12. Type of Reporting Person (See Instructions): OO

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Thomas R. Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:       95,000
    7. Sole Dispositive Power
    8. Shared Dispositive Power:       95,000

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:       95,000
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  .11%
    12. Type of Reporting Person (See Instructions): IN

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      Ann C. Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:       95,000
    7. Sole Dispositive Power
    8. Shared Dispositive Power:       95,000

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:       95,000
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  .11%
    12. Type of Reporting Person (See Instructions): IN

     

    1. Names of Reporting Persons
      I.R.S. Identification Nos. of above persons (entities only)
      J. Christopher Donahue
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)
      (b)
    3. SEC Use Only
    4. Citizenship or place of Organization: United States

     

    Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power:
    6. Shared Voting Power:       95,000
    7. Sole Dispositive Power
    8. Shared Dispositive Power:       95,000

     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person:       95,000
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    11. Percent of Class Represented by Amount in Row (9):  .11%
    12. Type of Reporting Person (See Instructions): IN

     

    Item 1.

    (a) Name of Issuer
      FUSION PHARMACEUTICALS, INC.
    (b) Address of Issuer’s Principal Executive Offices
      270 Longwood Road South
      Hamilton, Ontario, Canada, L8P 0A6

    Item 2.

    (a) Name of Person Filing: Federated Hermes, Inc.
    (b) Address Of Principal Business Office or, if none, Residence
      1001 Liberty Avenue, Pittsburgh, PA  15222-3779
    (c) Citizenship: Pennsylvania
    (d) Title of Class of Securities
      Common Stock
    (e) CUSIP Number: 36118A100
    Item 3.If this statement is filed pursuant to §§240.113d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)   An investment adviser in accordance with §204.13d-1(b)(1)(ii)(E);
    (f)   An employee benefit plan or endowment fund in accordance with §240.13d-19b)(1)(ii)(F);
    (g) X A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)   Group, in accordance with §240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    A. Federated Hermes, Inc.
    (a) Amount beneficially owned:       95,000
    (b) Percent of class:  .11%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:       95,000
      (ii) Shared power to vote or to direct the vote:  0
      (iii) Sole power to dispose or to direct the disposition of:       95,000
      (iv) Shared power to dispose or to direct the disposition of:  0

     

    B. Voting Shares Irrevocable Trust
    (a) Amount beneficially owned:       95,000
    (b) Percent of class:  .11%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:       95,000
      (ii) Shared power to vote or to direct the vote:  0
      (iii) Sole power to dispose or to direct the disposition of:       95,000
      (iv) Shared power to dispose or to direct the disposition of:  0

     

     

    C. Thomas R. Donahue
    (a) Amount beneficially owned:       95,000
    (b) Percent of class:  .11%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:       95,000
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:       95,000

     

    D. Ann C. Donahue
    (a) Amount beneficially owned:       95,000
    (b) Percent of class:  .11%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:       95,000
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:       95,000

     

     

    E. J. Christopher Donahue
    (a) Amount beneficially owned:       95,000
    (b) Percent of class:  .11%
    (c) Number of shares to which the person has:
      (i) Sole power to vote or to direct the vote:  0
      (ii) Shared power to vote or to direct the vote:       95,000
      (iii) Sole power to dispose or to direct the disposition of:  0
      (iv) Shared power to dispose or to direct the disposition of:       95,000

    The share amounts stated in Item 4 exclude ownership of 10,716,153 shares previously disclosed on a 13D filing made on March 25, 2024

    Instruction: Dissolution of a group requires a response to this item.

    Item 5.Ownership of Five Percent or Less of a Class X

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:

    Instruction: Dissolution of a group requires a response to this item.

    Item 6.Ownership of More than Five Percent on Behalf of Another Person. NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See Exhibit “1” Attached
    Item 8.Identification and Classification of Members of the Group: NOT APPLICABLE
    Item 9.Notice of Dissolution of Group: NOT APPLICABLE
    Item 10.Certification
    (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b);
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.
    (b) The following certification shall be included if the statement is filed pursuant to §204.13d-1(c):
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: April 8, 2024
    By: /s/J. Christopher Donahue
    Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
       
    Date: April 8, 2024
    By: /s/Thomas R. Donahue
    Name/Title Thomas R. Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       
    Date: April 8, 2024
    By: /s/Ann C. Donahue
    Name/Title: Ann C. Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       
    Date: April 8, 2024
    By: /s/J. Christopher Donahue
    Name/Title J. Christopher Donahue individually and as Trustee of Voting Shares Irrevocable Trust
       

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See U.S.C. 1001)

     
     

     

    EXHIBIT “1”

    ITEM 3 CLASSIFICATION OF REPORTING PERSONS

    Identity and Classification of Each Reporting Person

     

    IDENTITY CLASSIFICATION UNDER ITEM 3
    Federated Hermes World Investment Series, Inc. (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
    Federated Global Investment Management Corp. (e) Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940
    Federated Hermes, Inc. (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    FII Holdings, Inc. (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Voting Shares Irrevocable Trust (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Thomas R. Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    Ann C. Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)
    J. Christopher Donahue (g) parent Holding Company or control person, in accordance with Section 240.13d-1(b)(ii)(G)

    Federated Hermes, Inc. (the “Parent”) is filing this schedule 13G because it is the parent holding company of Federated Global Investment Management Corp. (the “Investment Adviser”), which acts as investment adviser to registered investment companies and separate accounts that own shares of common stock in FUSION PHARMACEUTICALS, INC. (the “Reported Securities”). The Investment Adviser is a wholly owned subsidiary of FII Holdings, Inc., which is a wholly owned subsidiary of Federated Hermes, Inc., the Parent. All of the Parent’s outstanding voting stock is held in the Voting Shares Irrevocable Trust (the “Trust”) for which Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue act as trustees (collectively, the “Trustees”). The Trustees have joined in filing this Schedule 13G because of the collective voting control that they exercise over the Parent. In accordance with Rule 13d-4 under the Securities Act of 1934, as amended, the Parent, the Trust, and each of the Trustees declare that this statement should not be construed as an admission that they are the beneficial owners of the Reported Securities, and the Parent, the Trust, and each of the Trustees expressly disclaim beneficial ownership of the Reported Securities.

     
     

    EXHIBIT “2”

    AGREEMENT FOR JOINT FILING OF

    SCHEDULE 13G

    The following parties hereby agree to file jointly the statement on Schedule 13G to which this Agreement is attached and any amendments thereto which may be deemed necessary pursuant to Regulation 13D-G under the Securities Exchange Act of 1934:

    1.       Federated Hermes, Inc. as parent holding company of the investment advisers to registered investment companies that beneficially own the securities.

    Voting Shares Irrevocable Trust, as holder of all the voting shares of Federated Hermes, Inc.

    Thomas R. Donahue, individually and as Trustee

    Ann C. Donahue, individually and as Trustee

    J. Christopher Donahue, individually and as Trustee

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other parties unless such party knows or has reason to believe that such information is incomplete or inaccurate.

    It is understood and agreed that the joint filing of Schedule 13G shall not be construed as an admission that the reporting persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.

    Date: April 8, 2024

    By: /s/J. Christopher Donahue
    Name/Title: J. Christopher Donahue, as President of Federated Hermes, Inc.
       
    By: /s/Thomas R. Donahue
    Name/Title Thomas R. Donahue, individually and as Trustee of Voting Shares Irrevocable Trust.
       
    By: /s/Ann C. Donahue
    Name/Title Ann C. Donahue, individually and as Trustee of Voting Shares Irrevocable Trust
       
    By: /s/J. Christopher Donahue
    Name/Title J. Christopher Donahue, individually and as Trustee of Voting Shares Irrevocable Trust

    1.       The number of shares indicated represent shares beneficially owned by registered investment companies and separate accounts advised by subsidiaries of Federated Hermes, Inc. that have been delegated the power to direct investment and power to vote the securities by the registered investment companies’ board of trustees or directors and by the separate accounts’ principals. All of the voting securities of Federated Hermes, Inc. are held in the Voting Shares Irrevocable Trust (“Trust”), the trustees of which are Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue (“Trustees”). In accordance with Rule 13d-4 under the 1934 Act, the Trust, Trustees, and parent holding company declare that the filing of this statement should not be construed as an admission that any of the investment advisers, parent holding company, Trust, and Trustees are beneficial owners (for the purposes of Sections 13(d) and/or 13(g) of the Act) of any securities covered by this statement, and such advisers, parent holding company, Trust, and Trustees expressly disclaim that they are the beneficial owners of such securities.

     
     

     

    EXHIBIT “3”

     

     

    EXHIBIT “3”

     

     

     

    Text, letter

Description automatically generated

    Get the next $FUSN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FUSN

    DatePrice TargetRatingAnalyst
    12/27/2023$12.00 → $15.00Outperform → Strong Buy
    Raymond James
    9/29/2023$13.00Outperform
    Oppenheimer
    6/23/2023$13.00Outperform
    Raymond James
    12/1/2022$10.00Buy
    B. Riley Securities
    11/30/2022$6.00Outperform
    SVB Leerink
    9/16/2022$10.00Buy
    Truist
    7/6/2022Outperform
    William Blair
    10/19/2021$19.00Overweight
    Morgan Stanley
    More analyst ratings

    $FUSN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fusion Pharmaceuticals upgraded by Raymond James with a new price target

    Raymond James upgraded Fusion Pharmaceuticals from Outperform to Strong Buy and set a new price target of $15.00 from $12.00 previously

    12/27/23 7:28:15 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Fusion Pharmaceuticals with a new price target

    Oppenheimer initiated coverage of Fusion Pharmaceuticals with a rating of Outperform and set a new price target of $13.00

    9/29/23 7:21:03 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James initiated coverage on Fusion Pharmaceuticals with a new price target

    Raymond James initiated coverage of Fusion Pharmaceuticals with a rating of Outperform and set a new price target of $13.00

    6/23/23 8:57:58 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FUSN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acquisition of Fusion Pharmaceuticals Completed

    HAMILTON, ON and BOSTON, June 4, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca AB by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement. The Arrangement marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more

    6/4/24 4:05:00 PM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement

    HAMILTON, ON and BOSTON, May 31, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced it has obtained a final order from the Ontario Superior Court of Justice (Commercial List) approving the previously announced statutory plan of arrangement under Section 192 of the Canada Business Corporations Act, pursuant to which a wholly-owned subsidiary of AstraZeneca will acquire all issued and outstanding shares of Fusion (the "Arrangement"). Fusion shareholders will receive US$21.00 per share in cash upfront on completion of the Arrangement plus a deferred

    5/31/24 4:05:00 PM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca

    HAMILTON, ON and BOSTON, May 29, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that at a special meeting of its shareholders (the "Shareholders"), held virtually earlier today, the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion (the "Arrangement").

    5/29/24 4:05:00 PM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FUSN
    SEC Filings

    View All

    SEC Form 15-12G filed by Fusion Pharmaceuticals Inc.

    15-12G - Fusion Pharmaceuticals Inc. (0001805890) (Filer)

    6/17/24 6:05:27 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Fusion Pharmaceuticals Inc.

    EFFECT - Fusion Pharmaceuticals Inc. (0001805890) (Filer)

    6/10/24 12:15:06 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Fusion Pharmaceuticals Inc.

    EFFECT - Fusion Pharmaceuticals Inc. (0001805890) (Filer)

    6/10/24 12:15:07 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FUSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bitetti Teresa Marie

    4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)

    6/4/24 5:35:41 PM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gannon Steven returned 56,400 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)

    6/4/24 5:31:40 PM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Valliant John returned 318,147 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)

    6/4/24 5:31:38 PM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FUSN
    Financials

    Live finance-specific insights

    View All

    Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R

    Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in this Arm is Currently Enrolling Data to be Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting Fusion to Host Conference Call Tomorrow, Tuesday, June 27th at 4:00 p.m. ET/3:00 p.m. CT   HAMILTON, ON and BOSTON, June 26, 2023 /PRNewswire/ --  Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of interim data from the do

    6/26/23 8:05:00 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates

    Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expected in Q2 2023 FPI-1966 and FPI-2059 Phase 1 trials open and recruiting patients Strong balance sheet with runway into Q1 2025 supports ongoing execution of multiple clinical programs HAMILTON, ON and BOSTON, March 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2022 and provided an updat

    3/16/23 7:30:00 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update

    Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions HAMILTON, ON and BOSTON, May 11, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2021 and provided an update on clinical and corporate developments. "We continue to advance our Phase 1 study

    5/11/21 7:30:00 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FUSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Fusion Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)

    4/8/24 9:10:09 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Fusion Pharmaceuticals Inc.

    SC 13D - Fusion Pharmaceuticals Inc. (0001805890) (Subject)

    3/25/24 5:29:36 PM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Fusion Pharmaceuticals Inc. (Amendment)

    SC 13D/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)

    3/20/24 6:08:58 PM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FUSN
    Leadership Updates

    Live Leadership Updates

    View All

    Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates

    FPI-1434 Phase 1 data on track to be reported in first half of 2023 Phase 1/2 Study of FPI-1966 open and enrolling patients with solid tumors expressing FGFR3 Strong balance sheet with $205.5 million in cash, cash equivalents and investments with runway into Q3 2024 HAMILTON, ON and BOSTON, Nov. 8, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the third quarter ended September 30, 2022 and provided an update on clinical and corporate developments.

    11/8/22 7:00:00 AM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. as Chief Medical Officer

    HAMILTON, ON and BOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer. "We are pleased to welcome Dmitri to Fusion's leadership team at a time when Fusion has three Phase 1 novel targeted alpha therapy (TAT) programs and a multi-product development collaboration with AstraZeneca," said Fusion Chief Executive Officer John Valliant, Ph.D. "Dmitri brings to

    11/7/22 4:25:00 PM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer

    - Eric Burak, Ph.D. Appointed as Chief Technology Officer HAMILTON, Ontario and BOSTON, Nov. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer. Dr. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals. "Chris' expertise and success in radiopharmaceutical research and development is scarce in our

    11/2/21 4:15:00 PM ET
    $FUSN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care